2450: Post-TED

Centers participating in the CIBMTR must submit a Post-TED (2450) Form for recipients who meet any of the following criteria:

• Recipient receives a transplant at a United States center designated as a TED-only center.
• Recipient receives a transplant at a United States center designated as Comprehensive Report Form center but has been assigned to the TED track by the Form Selection Algorithm.
• Recipient receives an allogeneic transplant at a United States center designated as Comprehensive Report Form center but has not consented to participate in research.
• Recipient receives a transplant at an international center, has consented to participate in research, and has been assigned to the TED track by the Form Selection Algorithm.

The Post-TED fulfills the requirements of the SCTOD for recipients meeting any of the above criteria. For more information regarding the SCTOD, see SCTOD Requirements.

For more information, including information on the TED and Comprehensive Report Form Selection Algorithm, see Section 1 in the Center Reference Guide.

The Post-TED (2450) Form must be completed at the following time points: 100 days, six months, and annually post-infusion. These forms should be completed as closely to these time points as possible. The structure of the TED Forms is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms, except in the case of a subsequent infusion.

*Reporting Data for Each Reporting Period
If the Post-TED (2450) is completed for the Day 100 reporting period, answers to all questions should reflect Day +1 until, and including, the reported Day 100 contact date. For the six-month or annual evaluations, the answers to all questions should reflect since the contact date for the prior reporting period until, and including, the reported contact date for the current reporting period.

*Subsequent Infusions
If the recipient received a subsequent infusion (excluding DLIs, allogeneic boosts using a previous donor for poor graft function / insufficient donor chimerism, and autologous rescues), the answers to all questions should reflect the clinical status of the recipient the day prior to the start of the preparative regimen or, if no preparative regimen was given, the answers to all questions should reflect the clinical status of the recipient the day prior to infusion.

Subsequent Infusions

If a recipient receives a subsequent HCT between Post-TED time points (100 day, six months, annually), the TED form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure or an allogeneic infusion using a prior donor for poor graft function / insufficient donor chimerism, the form sequence will not start over again . Generally, these types of infusions (autologous rescue and allogeneic boosts) are used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease. The Indication for CIBMTR Data Reporting (2814) will come due for both autologous rescues and allogeneic boosts; however, after completing the form, the Donor Cellular Infusion (2199) will come only come due for allogeneic boosts.

Contact the CIBMTR Customer Service Center if the subsequent Pre-TED (2400) does not come due automatically.

Combined Follow-Up

In scenarios where both HCT and cellular therapy forms are being completed, duplicate questions between HCT and cellular therapy forms may be disabled on the Post-TED (2450). A full list of enabled and disabled data fields can be found on the Combined Follow Up section of the Data Management Guide. Illustrations of the combined follow up scenarios can also be found the in the Data Management Guide.

Non-Malignant Diseases

If the HCT being reported was given to treat a non-malignant disease (as reported on the Pre-TED Disease Classification (2402) Form), do not complete the following sections of the Post-TED (2450) Form:

• Disease Assessment at the Time of Best Response to Infusion
• First Relapse or Progression Post-Infusion
• Post-Infusion Intervention for Disease
• Post-Infusion Treatment Given to Prevent Relapse or Progression
• Fecal Microbiota Transplant (FMT)
• Current Disease Status
  

Lost to Follow-Up

Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient’s moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up tool in FormsNet3^SM for each reporting period in which no contact exists.

Links to Sections in Manual:
Q1 – 2: Survival
Q3: Subsequent Transplant
Q4 – 6: Initial ANC Recovery
Q7 – 8: Initial Platelet Recovery
Q9 – 33: Graft-Versus-Host Disease
Q34 – 36: Liver Toxicity Prophylaxis
Q37 – 38: Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Q39: New Malignancy, Lymphoproliferative or Myeloproliferative Disorder
Q40: Chimerism Studies
Q41 – 66: Disease Assessment at the Time of Best Response to Infusion
Q67 – 73: First Relapse or Progression Post-Infusion
Q74 – 76: Recurrence of Non-Malignant Disease
Q77 – 84: Post-Infusion Intervention for Disease
Q85 – 91: Post-Infusion Treatment Given to Prevent Relapse or Progression
Q92 – 95: Fecal Microbiota Transplant
Q96 – 98: Current Disease Status

Manual Updates
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

To reference the historical Manual Change History for this form, review the retired manual section on the Retired Forms Manual webpage.

Date	Manual Section	Add/Remove/Modify	Description
10/24/2025	2450: Post-TED	Modify	Version 8 of the 2450: Post-TED section of the Forms Instruction Manual released. Version 8 corresponds to revision 9 of the Form 2450.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.